atitis C drugs, a new target could soon emerge in the form of a new class of cholesterol busting medicines that includes Regeneron (NASDAQ:REGN) and Sanofi SA's (NYSE:SNY) recently- approved Praluent. The FDA gave Regeneron and Sanofi a green light to begin selling Praluent last week, and the two companies